Moreover, the long multi-epitope peptide constructed from MHCI (BIRC5 and EphA2) and MHCII (PADRE)-restricted peptides combined with adjuvants such as lenalidomide and anti-PD1 has the potential to enhance the immunotherapeutic effects in the GBM mouse model. Here, BIRC5 is linked to glioblastoma.